

Performance (consolidated)

(¥ million)

	2016 (JGAAP)	2017 (JGAAP)	2018 (JGAAP)	2019 (JGAAP)	2020 (JGAAP)	2021 (JGAAP)	2022 (IFRS) (estimated)
Net Sales	98,781	101,448	114,716	116,637	121,885	137,547	134,000
Operating profit	15,280	17,079	20,644	21,668	26,134	28,299	27,000
Ordinary Profit	16,244	17,451	21,540	22,442	26,760	29,773	27,500
Profit attributable to owners of parent	11,749	12,953	16,302	16,866	20,702	23,044	21,500

May 11, 2022

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2020 (JGAAP)	Sales 2021 (JGAAP)	Sales 2022 (IFRS) (estimated)	
						Apr-Sep	Annual
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	15,350	18,338	7,800	12,400
Upravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	6,804	8,400	4,500	9,800
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	2,387	7,750	5,900	13,000
(Japan)				(1,953)	(4,059)	(2,200)	(4,750)
(U.S.)				(434)	(3,691)	(3,700)	(8,250)
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	6,906	6,770	2,700	5,000
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-2018	5,312	5,300	2,700	5,800
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	5,474	4,563	1,400	2,500
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	6,743	4,106	1,300	2,300
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,677	2,532	1,250	2,600
Erizas	dexamethasone cipeccilate	allergic rhinitis	Dec-2009	2,444	2,330	700	2,400
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	1,970	2,128	1,000	2,300
Profit in co-promotion				8,442	8,934	4,600	9,500
Revenues from the licensing of industrial property rights				24,338	33,207	14,600	29,800
Pharmaceuticals				106,478	120,650	57,400	115,000
Functional Food				15,406	16,897	9,600	19,000
Net Sales				121,885	137,547	67,000	134,000

\* Estimated sales for 2022 is disclosed in International Financial Reporting Standards (IFRS).